Thousand Oaks mayor lauds ‘balanced growth,’ cites new mixed-use project
Thousand Oaks mayor Al Adam gave the annual State of the City address on Dec. 8, centered around three things he said are most important to the city’s growth: jobs, the environment and housing. In his virtual address, Adam said the influx of biotech companies in recent years has been a big win for the Read More →
Read More →Amgen joins new cooperative trials for COVID treatment
With COVID-19 continuing to surge across the globe, a coalition of pharmaceutical companies including Thousand Oaks-based Amgen has announced a joint trial for new coronavirus treatments. Amgen, along with Takeda and UCB, are now collaborating to study methods of treatment for patients who are hospitalized due to COVID-19, the three companies announced. The trial enrolled Read More →
Read More →
Inphi, Marvell to form $40 billion chip giant
Marvell’s acquisition put’s Inphi’s Thousand Oaks operation in question
Read More →Marvell to buy Inphi in $8B semiconductor deal
Marvell Technology Group, a major semiconductor company, announced Oct. 29 it will acquire Inphi, a competitor based in Santa Clara with significant operations in Thousand Oaks, in a cash and stock deal worth about $8 billion. Under the agreement, Marvell will pay Inphi shareholders $66 for each share of Inphi stock, along with 2.323 shares Read More →
Read More →Amgen beats expectations in Q3 earnings report
Amgen, one of the biggest biopharmaceutical companies in the world, continued to see growth in the third quarter of 2020, despite the COVID-19 pandemic. The Thousand Oaks-based company saw total revenue of $6.4 billion for the quarter, up 12 percent from the third quarter of 2019. Earnings per share increased 5 percent to $3.43. Both Read More →
Read More →Teledyne reports earnings dip
Despite a dip in earnings and sales compared to last year, Teledyne Technologies beat analysts’ expectations with net income of $93.9 million in the third quarter, the company announced Oct. 21. Analysts estimated that Teledyne’s diluted earnings per share would be $2.36 in the third quarter, according to estimates compiled by the Wall Street Journal. Read More →
Read More →Arcutis shares up on news of public, private offerings
Arcutis Biotherapeutics saw a 15 percent rise in its share price after it said Sept. 29 that it will offer 4 million shares to the public and sell another $35 million in stock to an affiliate of one of its directors. Arcutis closed at $31.04, a gain of $4.28 after it announced the dual track Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
